Abstract
Thiazide diuretics are often used in the treatment of arterial hypertension, although a number of side-effects, such as hypokalaemia, hyper-glycaemia and hyperuricaemia, caused by its prolonged administration, may diminish the benefits of its hypotensive effect (1). Loop diuretics, on the other hand, have not so far been recommended in this indication because of either its sharp and short-term activity or its kaliuretic effect. Muzolimine, a new pyrazolinone derivative loop diuretic with high-ceiling activity and prolonged action (2), was shown in animal studies to cause a kaliuresis lower than that by Furosemide (2). Taking into account these features, the present open trial was designed to investigate the antihypertensive effect of a single oral dose (30 mg once a day) of Muzolimine in a group of overweight, elderly hypertensive patients who are more likely to develop metabolic side-effects on diuretic therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
